Laura Helbling's profile photo

Laura Helbling

Washington, D.C.

Senior Writer, The RPM Report and Research Director at Prevision Policy

Director of Research at Prevision Policy; Senior Writer for The RPM Report Covering pharma and biotech regulation and policy.

Articles

  • 1 week ago | insights.citeline.com | Laura Helbling

    BIOSECURE Act Returning, Privacy, Gain-of-Function Bills Coming, Senate Sponsor Says Legislation prohibiting work with certain Chinese biopharma firms will be reintroduced soon, Democratic Sen. Gary Peters said. And it will not be the only bill tied to international biotech competition and security concerns that will be considered. The updated BIOSECURE Act will include adjustments based on issues that arose when the legislation was moving in 2024. (Shutterstock)

  • 3 weeks ago | insights.citeline.com | Laura Helbling

    US FDA Rare Disease Case Studies Provide Development Models For SponsorsSanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices. The rare disease case studies continue FDA efforts to educate sponsors on the best practices for rare disease product development. (Shutterstock)

  • Mar 6, 2025 | insights.citeline.com | Laura Helbling

    Vertex Non-Opioid Pain Drug Draws Bipartisan Support In House HearingCongress continues to offer broad support for encouraging alternatives to opioid pain medicine, including proposals to speed coverage of new agents like Vertex’ Journavx. Capitol Hill is pushing for better insurance coverage of non-opioid pain medications. (Shutterstock)

  • Nov 21, 2024 | insights.citeline.com | Laura Helbling

    Dose Optimization And Rare Diseases: Doing More With LessUS FDA officials said dose optimization for rare diseases should not be sacrificed in the name of speeding access to medicines, but is the oncology approach spreading to rare diseases? The FDA said dose optimization may be more important for rare diseases because the small patient populations limit the number of possible clinical trials. (Shutterstock)

  • Oct 4, 2024 | pink.citeline.com | Laura Helbling

    Analysis Executive Summary Prior authorization reforms could emerge as an important under-the-radar area of drug policy next year. An upcoming Medicare proposed rule, the extraordinary uptake of weight loss therapies, and the launch of the overhauled Part D benefit design will all drive attention to the issue. Source: Shutterstock Existing Subscriber? Sign in to continue reading. New to Pink Sheet?

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
803
Tweets
4K
DMs Open
No
Laura Helbling
Laura Helbling @Laura_H
12 May 25

RT @jeanniereporter: @BGOV @erinmdurkin But groups like @RareDiseases have been pushing to allow multiple indications for the Orphan Drug A…

Laura Helbling
Laura Helbling @Laura_H
25 Apr 25

For dx followers, boosting this FDA safety comm from yesterday on Magellan Diagnostics LeadCare Testing Systems: https://t.co/xLfI1lrcGw

Laura Helbling
Laura Helbling @Laura_H
24 Apr 25

RT @matthewherper: No new autism registry, HHS says walking back NIH director's claim https://t.co/nMpe92c5XJ